318 related articles for article (PubMed ID: 24602499)
1. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.
Falagas ME; Vardakas KZ; Tsiveriotis KP; Triarides NA; Tansarli GS
Int J Antimicrob Agents; 2014 Jul; 44(1):1-7. PubMed ID: 24602499
[TBL] [Abstract][Full Text] [Related]
2. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients.
Balandin Moreno B; Fernández Simón I; Pintado García V; Sánchez Romero I; Isidoro Fernández B; Romera Ortega MA; Alcántara Carmona S; Pérez Redondo M; Galdos Anuncibay P
Scand J Infect Dis; 2014 Mar; 46(3):175-80. PubMed ID: 24354959
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
[TBL] [Abstract][Full Text] [Related]
4. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
5. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
[TBL] [Abstract][Full Text] [Related]
6. A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study).
Mustafa M; Chan WM; Lee C; Harijanto E; Loo CM; Van Kinh N; Anh ND; Garcia J
Int J Antimicrob Agents; 2014 Apr; 43(4):353-60. PubMed ID: 24636429
[TBL] [Abstract][Full Text] [Related]
7. A practice-based observational study identifying factors associated with the use of high-dose tigecycline in the treatment of secondary peritonitis in severely ill patients.
Maseda E; Suárez-de-la-Rica A; Anillo V; Salgado P; Tamayo E; García-Bernedo CA; Ramasco F; Villagrán MJ; López-Tofiño A; Giménez MJ; Granizo JJ; Hernández-Gancedo C; Aguilar L; Gilsanz F
Rev Esp Quimioter; 2015 Feb; 28(1):47-53. PubMed ID: 25690145
[TBL] [Abstract][Full Text] [Related]
8. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.
Poulakou G; Kontopidou FV; Paramythiotou E; Kompoti M; Katsiari M; Mainas E; Nicolaou C; Yphantis D; Antoniadou A; Trikka-Graphakos E; Roussou Z; Clouva P; Maguina N; Kanellakopoulou K; Armaganidis A; Giamarellou H
J Infect; 2009 Apr; 58(4):273-84. PubMed ID: 19344841
[TBL] [Abstract][Full Text] [Related]
9. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C
Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients.
Kuo SC; Wang FD; Fung CP; Chen LY; Chen SJ; Chiang MC; Hsu SF; Liu CY
J Microbiol Immunol Infect; 2011 Feb; 44(1):45-51. PubMed ID: 21531352
[TBL] [Abstract][Full Text] [Related]
11. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic evaluation of tigecycline.
Giamarellou H; Poulakou G
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1459-70. PubMed ID: 21958044
[TBL] [Abstract][Full Text] [Related]
13. Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.
Cprek JB; Gallagher JC
Antimicrob Agents Chemother; 2016 Jan; 60(1):669-73. PubMed ID: 26552970
[TBL] [Abstract][Full Text] [Related]
14. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
Freire AT; Melnyk V; Kim MJ; Datsenko O; Dzyublik O; Glumcher F; Chuang YC; Maroko RT; Dukart G; Cooper CA; Korth-Bradley JM; Dartois N; Gandjini H;
Diagn Microbiol Infect Dis; 2010 Oct; 68(2):140-51. PubMed ID: 20846586
[TBL] [Abstract][Full Text] [Related]
15. Tigecycline: an update.
Stein GE; Babinchak T
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
Xie J; Roberts JA; Alobaid AS; Roger C; Wang Y; Yang Q; Sun J; Dong H; Wang X; Xing J; Lipman J; Dong Y
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607024
[TBL] [Abstract][Full Text] [Related]
17. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
Bassetti M; McGovern PC; Wenisch C; Meyer RD; Yan JL; Wible M; Rottinghaus ST; Quintana A
Int J Antimicrob Agents; 2015 Sep; 46(3):346-50. PubMed ID: 26155003
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
[TBL] [Abstract][Full Text] [Related]
19. Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.
Wu X; Zhu Y; Chen Q; Gong L; Lin J; Lv D; Feng J
Biomed Res Int; 2016; 2016():8395268. PubMed ID: 28044137
[No Abstract] [Full Text] [Related]
20. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
